Peptichemio in pretreated patients with plasmacell neoplasms

Adriano Paccagnella, Luigi Salvagno, Vanna Chiarion-Sileni, Sandro Bolzonella, Pietro de Besi, Michela Frizzarin, Giovanni L. Pappagallo, Vinicio P. Fosser, Adriano Fornasiero, Romana Segati, Mario V. Fiorentino

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-one patients with alkylator-resistant plasmacell neoplasms were treated with Peptichemio (PTC) at a dose of 40 mg/m2 for 3 days every 3 weeks or, in the case of persistent leukopenia and/or thrombocytopenia, at the single dose of 70 mg/m2 every 2-3 weeks according to haematological recovery. Seventeen patients, 10 with multiple myeloma and seven with extramedullary plasmacytoma (EMP), were fully evaluable. Six of 17 patients (35%) responded: three of seven EMP patients had a complete remission and 3 of 10 multiple myeloma patients had an objective response 50%. The median duration of response was 8.5 months. An EMP patient obtained a complete response lasting for 16 months. The most frequent toxic effect were phlebosclerosis, occurring in all the patients, and myelosuppression, which was severe in only one case. PTC appears to be an active drug in patients with plasmacell neoplams even if resistant to alkylating agents.

Original languageEnglish
Pages (from-to)1053-1058
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number9
DOIs
Publication statusPublished - 1986

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Peptichemio in pretreated patients with plasmacell neoplasms'. Together they form a unique fingerprint.

Cite this